[Relationship between TNFalpha and tumor rejection induced by a single dose of melphalan in C57BL/6 mice].
OBJECTIVE
To investigate the relationship between TNFalpha and tumor rejection induced by a single dose of melphalan in C57BL/6 mice.


METHODS
Different gene type mice (TNFR1(+/+), TNFR1(+/-) and TNFR1(-/-)) with the same genetic background of C57BL/6 were used in this experiment. Murine lymphoma EL4 cells were inoculated subcutaneously into the different gene type mice simultaneously. Twelve days later, 7.5 mg/kg melphalan was used intraperitoneally to treat the tumor-bearing mice with TNFR1(+/+), TNFR1(+/-) and TNFR1(-/-). The tumors in the different gene type mice were observed and recorded every one to three day.


RESULTS
After the treatment of 7.5 mg/kg melphalan during the first week, the tumors in the different gene type mice shrank at a similar rate. In the following 2 months, the tumors in the TNFR1(+/+) and TNFR1(+/-) C57BL/6 mice gradually shrank and were cured but most tumors in the TNFR1(-/-) C57BL/6 mice relapsed after melphalan treatment.


CONCLUSIONS
TNFalpha plays an important role in melphalan-induced tumor rejection. The anti-tumor effect of melphalan has no relationship with the expression of tumor necrosis factor 1 in tumor-bearing mice. TNFR1 is required to prevent or avoid the relapse of tumors in mice instead of tumor cells.
Li
Mo-Lin
ML
Department of Pathophysiology, Dalian Medical University, Dalian 116027, China.
Li
Chuan-Gang
CG
Shu
Xiao-Hong
XH
Jiang
Miao-Na
MN
Jia
Yu-Jie
YJ
Qin
Zhi-Hai
ZH
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005838:Genotype; D008223:Lymphoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D018906:Antineoplastic Agents, Alkylating; D047888:Receptors, Tumor Necrosis Factor, Type I; C506236:Tnfrsf1a protein, mouse; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan